Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atrioventricular block

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Atrioventricular block. Displaying page 1 of 1.
    EudraCT Number: 2017-002475-26 Sponsor Protocol Number: GD2CAR01 Start Date*: 2017-12-22
    Sponsor Name:IRCCS Ospedale Pediatrico Bambino Gesù
    Full Title: Phase I/II study of anti-GD2 Chimeric Antigen Receptor-Expressing T cells in pediatric patients affected by High Risk and/or relapsed/refractory Neuroblastoma
    Medical condition: High Risk and/or relapsed/refractory Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10019260 Heart block AV third degree LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-003861-39 Sponsor Protocol Number: GLUCOTAVI Start Date*: 2023-03-07
    Sponsor Name:JUAN MIGUEL RUIZ NODAR
    Full Title: Glucocorticoid treatment in patients undergoing TAVI to reduce the incidence of atrioventricular block and pacemaker implantation
    Medical condition: aortic stenosis
    Disease:
    Population Age: Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003912-99 Sponsor Protocol Number: CMP-MYTHiC Start Date*: 2023-05-09
    Sponsor Name:AZIENDA OSPEDALIERA AO OSPEDALE NIGUARDA CA' GRANDA
    Full Title: Single-blinded randomized investigator-driven controlled trial to assess the efficacy of colchicine to treat patients with cardiomyopathy with myocarditis (chronic inflammatory cardiomyopathy) CMP...
    Medical condition: Cardiomyopathy with myocarditis (chronic inflammatory cardiomyopathy)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007636 Cardiomyopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002708-38 Sponsor Protocol Number: 131313 Start Date*: 2020-10-26
    Sponsor Name:Department of Medical Science Gothenburg University
    Full Title: Optimized pharmacological treatment for broken heart (takotsubo) syndrome
    Medical condition: The medical condition is acute heart failure (Takotsubo syndrome)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-002541-11 Sponsor Protocol Number: P170912J Start Date*: 2019-06-06
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Prevention of post-operative Atrial Fibrillation by BOTulinum toxin injections into epicardial fat pads around pulmonary veins in patients undergoing cardiac surgery
    Medical condition: Adult patients with indication for conventional cardiac surgery (CABG, aortic replacement, or ascending aorta surgery) will be eligible
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004865 10067824 Prophylaxis against atrial fibrillation LLT
    Population Age: Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-001781-14 Sponsor Protocol Number: POX-MVA-005 Start Date*: 2006-04-11
    Sponsor Name:Bavarian Nordic A/S
    Full Title: A partially randomized, partially double-blind, placebo-controlled Phase II non-inferiority study to evaluate immunogenicity and safety of one and two doses of MVA-BN (IMVAMUNE™) smallpox vaccine i...
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    8.0 10041197 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-006297-28 Sponsor Protocol Number: POX-MVA-023 Start Date*: 2008-07-30
    Sponsor Name:Bavarian Nordic A/S
    Full Title: An open-label Phase II study to evaluate immunogenicity and safety of a single IMVAMUNE® booster vaccination two years after the last IMVAMUNE® vaccination in former POX-MVA-005 vaccinees
    Medical condition: Healthy subjects - prevention of smallpox infection
    Disease: Version SOC Term Classification Code Term Level
    9.1 10041197 Smallpox PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003613-19 Sponsor Protocol Number: APHP210303 Start Date*: 2021-12-07
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: AbataCept for the treatment of immune-cHeckpoint inhibitors induced mYocarditiS
    Medical condition: All adult patients with cancer (all cancer types) treated by immune checkpoint inhibitors (anti-PD1, anti-PDL1, anti-CTLA4 monotherapies or combination) and presenting drug-induced myocarditis. The...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004263-36 Sponsor Protocol Number: RPL554-010-2015 Start Date*: 2016-12-07
    Sponsor Name:Verona Pharma plc
    Full Title: A Phase IIa, randomised, double blind, placebo controlled, three way crossover study to assess the pharmacokinetics of RPL554 administered to adult patients with Cystic Fibrosis.
    Medical condition: Cystic Fibrosis (CF)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10011762 Cystic fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000388-18 Sponsor Protocol Number: DIAS-001-FFR Start Date*: 2016-03-24
    Sponsor Name:Diasolve Ltd
    Full Title: A randomised crossover investigation to evaluate and compare the effectiveness, safety and feasibility of a novel dedicated Over-The-Wire FFR Infusion MicroCatheter (HYPEREM IC) for measuring fract...
    Medical condition: This is a single‐blind, randomised, crossover investigation comparing the investigational device using intra‐coronary (IC) Adenosine infusion to the standard intravenous (IV) infusion method used f...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001732-25 Sponsor Protocol Number: PBF-680CT-06 Start Date*: 2021-08-13
    Sponsor Name:Palobiofarma, S.L
    Full Title: A phase IIa, randomized, double blind, placebo-controlled study to assess the effect of PBF-680 in patients with moderate to severe COPD on top of standard medication.
    Medical condition: Patients with moderate to severe Chronic Obstructive Pulmonar Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-001466-37 Sponsor Protocol Number: A-STAMI Start Date*: 2021-07-08
    Sponsor Name:Västra Götalandsregionen, Sahlgrenska University Hospital
    Full Title: Adenosine’s effect on STunning resolution in Acute Myocardial Infarction
    Medical condition: Acute Myocardial Infarction
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10000891 Acute myocardial infarction PT
    20.0 10007541 - Cardiac disorders 10000930 Acute myocardial infarction, unspecified site, initial episode of care LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-001245-32 Sponsor Protocol Number: PGX-III-AP-002 Start Date*: 2011-10-19
    Sponsor Name:Forest Laboratories, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind Trial of Apadenoson for the Detection of Myocardial Perfusion Defects Using Single-Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)
    Medical condition: Coronary Artery Disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022338-10 Sponsor Protocol Number: H9H-MC-JBAK Start Date*: 2011-05-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma
    Medical condition: Carcinoma, hepatocellular
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 13:27:13 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA